Roy S. Herbst, MD, PhD, of the Yale Cancer Center discussed his key takeaway from the phase III ADAURA trial regarding osimertinib as adjuvant therapy to treat NSCLC presented at the 2020 ASCO Virtual Scientific Program.
Roy S. Herbst, MD, PhD, presented a late breaking abstract on behalf of his colleagues regarding the ADAURA trial, which analyzed osimertinib as an adjuvant therapy to treat patients with stage IB–IIIA EGFR mutation positive non-small cell lung cancer, at the 2020 ASCO Virtual Scientific Program.
My key takeaway is that biologic therapy works in lung cancer just like it worked in breast cancer 15 years ago with receptive [therapy]. You take the biology of the tumor; you give a targeted agent that can be given for long periods of time-in this case 3 years-you see that you prevent the disease from recurring. As we prevent the disease from metastasizing or spreading, that’s going to improve outcome. There won’t be disease popping up in the brain, the liver, the bone at the same extent. Here, 83% less likely. That, of course, is great for patients because they are living with this lung cancer. They want to live without lung cancer, without the morbidity, without the side effects of that cancer for as long as possible.